BOSTON ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for October:

Oct. 5-6
JMP Securities Healthcare Focus conference

Oct. 7-8
Cowen & Co. 12 th Annual Therapeutics Conference

Oct. 8
FDA approval decision date for Spectrum Pharmaceuticals' ( SPPI) colon cancer drug Fusilev.

Oct. 13
Presentation at the American Neurological Association meeting of detailed data from the phase III study of Avanir Pharmaceuticals' ( AVNR) Zenvia, an experimental drug for the treatment of uncontrollable laughing and crying episodes -- a condition known medically as pseudobulbar affect. Avanir announced positive top-line results from this study in August.
Third-quarter earnings: Johnson & Johnson ( JNJ) (before market open) and Gilead Sciences ( GILD - Get Report) (after market close.)

Oct. 14
The FDA's Peripheral and Central Nervous System Drug Advisory Committee will convene to review Acorda Therapeutics' ( ACOR - Get Report) fampridine (brand name Amaya). The proposed indication for Amaya is to improve the walking ability of patients with multiple sclerosis. Biogen Idec ( BIIB) is Acorda's marketing partner for Amaya.
Take note: The FDA's briefing documents for Amaya should be posted to the agency's web site on Oct. 12 or 13. When available, those documents can be found here.
Third-quarter earnings: Abbott Labs ( ABT) (before market open.)

Oct. 15
Third-quarter earnings: Cubist Pharmaceuticals ( CBST) (after market closes.)

Oct. 16-21
The American College of Rheumatology annual meeting in Philadelphia. Noteworthy clinical data expected for presentation includes Pfizer's ( PFE - Get Report) CP-690550 in rheumatoid arthritis and Rigel Pharmaceuticals' ( RIGL) R788 in rheumatoid arthritis

Oct. 19
FDA approval decision date for Amgen's ( AMGN) osteoporosis drug denosumab. If approved, Amgen will market the drug under the brand name Prolia.

Oct. 22
FDA's approval decision date for Acorda's drug Amaya.

Oct. 24-28
The Obesity Society annual meeting convenes in Washington, D.C. Detailed data from phase III studies of three closely watched weight-loss drugs will be presented at the meeting: Arena Pharmaceuticals' ( ARNA - Get Report) lorcaserin, Vivus' ( VVUS - Get Report) Qnexa and Orexigen Therapeutics' ( OREX) Contrave.

Oct. 30
FDA approval decision date for GTX's ( GTXI) Acapodene for the reduction of bone fractures in prostate cancer patients undergoing androgen deprivation therapy.
FDA approval decision date for Transcept Pharmaceuticals' ( TSPT) Intermezzo for insomnia.

Oct. 30-Nov. 4
The American Association for the Study of Liver Disease convenes in Boston. This is the most important meeting for hepatitis C drug research held on the U.S. every year. Stocks to watch include Vertex Pharmaceuticals ( TICKER) ( VRTX), InterMune ( ITMN), Pharmasset ( VRUS), Idenix Pharmaceuticals ( IDIX) and Anadys Pharmaceuticals ( ANDS).

Important clinical trials with potential data readouts or other biotech events expected in October:

Company: Protalix BioTherapeutics ( PLX)
Drug/indication: prGCD (Uplyso) in Gaucher's disease.

Company: Allos Therapeutics ( ALTH)
Commercial launch of Folotyn in peripheral T-cell lymphoma

Written by Adam Feuerstein in Boston

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.